ABC | Volume 111, Nº3, September 2018

Original Article Marino et al Adiponectin and IVUS-VH Coronary Plaque Characteristics Arq Bras Cardiol. 2018; 111(3):345-353 19. Van deWerf F, Bax J, BetriuA, Blomstrom-Lundqvist C, Crea F, Falk V, et al; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task ForceontheManagementofST-SegmentElevationAcuteMyocardialInfarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909-45. 20. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectinwithcoronaryheartdiseaseandmortality:theRanchoBernardo study. Am J Epidemiol 2007;165(2):164-74. 21. PischonT,GirmanCJ,HotamisligilGS,RifaiN,HuFB,RimmEB.Plasmaadiponectin levelsandriskofmyocardial infarction inmen.JAMA.2004;291(14):1730-7. 22. SchnabelR,MessowCM,LubosE,Espinola-KleinC,RupprechtHJ,BickelC,et al.Associationofadiponectinwithadverseoutcome incoronaryarterydisease patients: results from the AtheroGene study. Eur Heart J. 2008;29(5):649-57. 23. Forsblom C, Thomas MC, Moran J, Saraheimo M, Thorn L, Waden J, et al; FinnDiane Study Group. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med. 2011;270(4):346-55. 24. Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA. Adiponectin is associatedwith increasedmortality and heart failure in patients with stable ischemic heart disease: data from theHeart and Soul Study. Atherosclerosis. 2012;220(2):587-92. 25. RathmannW,HerderC.Adiponectinandcardiovascularmortality:evidence for “reverse epidemiology”. HormMetab Res. 2007;39(1):1-2. 26. Shoji T, Koyama H, Fukumoto S, Maeno T, Yokoyama H, Shinohara K, et al. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis. 2006;188(1):190-5. 27. Bigalke B, Stellos K, Geisler T, Seizer P, Mozes V, Gawaz M. High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease. Platelets. 2010;21(1):11-9. 28. Van de Voorde J, Pauwels B, Boydens C, Decaluwe K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62(11):1513-21. 29. Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J. 2009;73(2):343-51. 30. Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, Ogasawara D, et al. Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol. 2008;101(1):1-7. 31. Sawada T, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Low plasma adiponectin levels are associated with presence of thin-cap fibroatheroma in men with stable coronary artery disease. Int J Cardiol. 2010;142(3):250-6. 32. Shah AD, Kandula NR, Lin F, Allison MA, Carr J, Herrington D, et al. Less favorable body composition and adipokines in south asians compared to other U.S. ethnic groups: results from the MASALA and MESA studies. Int J Obes (Lond). 2016;40(4):639-45. 33. Yang WS, Chuang LM. Human genetics of adiponectin in the metabolic syndrome. J Mol Med (Berl). 2006;84(2):112-21. 34. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, et al. Adiponectin I164Tmutation is associatedwith themetabolic syndrome and coronary artery disease. J Am Coll Cardiol. 2004;43(7):1195-200. 35. G a r c i a - G a r c i a HM , C o s t a MA , S e r r u y s PW. I ma g i n g o f coronary atherosclerosis: intravascular ultrasound. Eur Heart J. 2010;31(20):2456-69. 36. Nicholls SJ, Hsu A, Wolski K, Hu B, BayturanO, Lavoie A, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55(21):2399-407. 352